Comparison 16. Everolimus + Bevacizumab versus IFN α‐2a + Bevacizumab.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
16.1 Progression‐free survival	1		Hazard Ratio (IV, Random, 95% CI)	Totals not selected
16.2 Overall survival	1		Hazard Ratio (IV, Random, 95% CI)	Totals not selected
16.3 Serious adverse events (Grade 3 or 4)	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
16.4 Response rate	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
16.5 Minor adverse events (Grade 1 or 2)	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected